Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Benson

Showing results (801-810 of 865) with videos related to

Pageof 87
Sort By:
Biochemical and Biophysical Research Communications|November 12, 2009
Perspectives on the formation of an interdisciplinary research teamM V Dodson, L L Guan, M E Fernyhough, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple MyelomaSarah A Holstein, Vera J Suman, Kouros Owzar, et al.
Blood|October 28, 2011
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effectDon M Benson, Courtney E Bakan, Shuhong Zhang, et al.
Kidney International|April 24, 2019
Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patientsSamih H Nasr, Surendra Dasari, John C Lieske, et al.
British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2011
Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME propertiesHans G F Richter, G M Benson, K H Bleicher, et al.
British Journal of Haematology|May 12, 2010
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylationKristie A Blum, Zhongfa Liu, David M Lucas, et al.
Clinical Pharmacology and Therapeutics|February 5, 2017
Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy TrialY K Cho, D W Sborov, M Lamprecht, et al.
International Immunology|June 6, 2018
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemiaNathaniel J Buteyn, Kavin Fatehchand, Ramasamy Santhanam, et al.
Leukemia & Lymphoma|December 1, 2012
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myelomaNeil C Dunavin, Lai Wei, Patrick Elder, et al.
Pageof 87

Showing results (801-810 of 865) with videos related to

Sort By:
Pageof 87
Biochemical and Biophysical Research Communications|November 12, 2009
Perspectives on the formation of an interdisciplinary research teamM V Dodson, L L Guan, M E Fernyhough, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 24, 2020
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple MyelomaSarah A Holstein, Vera J Suman, Kouros Owzar, et al.
Blood|October 28, 2011
IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effectDon M Benson, Courtney E Bakan, Shuhong Zhang, et al.
Kidney International|April 24, 2019
Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patientsSamih H Nasr, Surendra Dasari, John C Lieske, et al.
British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2011
Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME propertiesHans G F Richter, G M Benson, K H Bleicher, et al.
British Journal of Haematology|May 12, 2010
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylationKristie A Blum, Zhongfa Liu, David M Lucas, et al.
Clinical Pharmacology and Therapeutics|February 5, 2017
Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy TrialY K Cho, D W Sborov, M Lamprecht, et al.
International Immunology|June 6, 2018
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemiaNathaniel J Buteyn, Kavin Fatehchand, Ramasamy Santhanam, et al.
Leukemia & Lymphoma|December 1, 2012
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myelomaNeil C Dunavin, Lai Wei, Patrick Elder, et al.
Pageof 87